varegacestat Updated Nov 10
The single most important catalyst is the FDA PDUFA decision on April 28, 2027. Approval would make varegacestat the second FDA-approved therapy for desmoid tumors and unlock a meaningful commercial opportunity, while a Complete Response Letter would severely pressure the stock given the company's pre-revenue status and reliance on this asset. Watch for EMA review progress and Q3 earnings on November 16 for pipeline updates and cash runway details.
- Phase 3 RINGSIDE data were exceptionally strong: varegacestat reduced the risk of progression or death by 84% vs placebo (HR=0.16, p<0.0001) and met all key secondary endpoints, setting a high bar for approval.
- The NDA was accepted by the FDA with a PDUFA date of April 28, 2027, and the EMA validated the MAA in October 2026, indicating dual-track regulatory progress.
- Immunome bought out all future milestone and royalty obligations to Bristol-Myers Squibb for $20M cash plus 4.43M shares, giving it full economic ownership of varegacestat with no future payment overhang.
- Varegacestat would enter a market with an existing approved therapy: SpringWorks Therapeutics' Ogsiveo (nirogacestat), which generated $172M in revenue in 2024 and is already established.
- Parabilis Medicines' zolucatetide (FOG-001), a beta-catenin inhibitor with a different mechanism, is in Phase 1/2 development for desmoid tumors and has orphan drug designation, representing future competition.
- Immunome is pre-revenue with accelerating cash burn: R&D expenses rose 41% YoY to $69.5M, and net loss widened to $85.8M in Q3 2026 from $57.5M a year earlier.